Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;9(5):1429-1443.
doi: 10.1111/andr.13041. Epub 2021 Jun 8.

The future direction of imaging in prostate cancer: MRI with or without contrast injection

Martina Pecoraro  1 , Emanuele Messina  1 , Marco Bicchetti  1 , Giorgia Carnicelli  1 , Maurizio Del Monte  1 , Beniamino Iorio  2 , Giuseppe La Torre  3 , Carlo Catalano  1 , Valeria Panebianco  1
Affiliations
Free article
Review

The future direction of imaging in prostate cancer: MRI with or without contrast injection

Martina Pecoraro et al. Andrology. 2021 Sep.
Free article

Abstract

Background: Multiparametric MRI (mpMRI) is the "state of the art" management tool for patients with suspicion of prostate cancer (PCa). The role of non-contrast MRI is investigated to move toward a more personalized, less invasive, and highly cost-effective PCa diagnostic workup.

Objective: To perform a non-systematic review of the existing literature to highlight strength and flaws of performing non-contrast MRI, and to provide a critical overview of the international scientific production on the topic.

Materials and methods: Online databases (Medline, PubMed, and Web of Science) were searched for original articles, systematic review and meta-analysis, and expert opinion papers.

Results: Several investigations have shown comparable diagnostic accuracy of biparametric (bpMRI) and mpMRI for the detection of PCa. The advantage of abandoning contrast-enhanced sequences improves operational logistics, lowering costs, acquisition time, and side effects. The main limitations of bpMRI are that most studies comparing non-contrast with contrast MRI come from centers with high expertise that might not be reproducible in the general community setting; besides, reduced protocols might be insufficient for estimation of the intra- and extra-prostatic extension and regional disease. The mentioned observations suggest that low-quality mpMRI for the general population might represent the main shortage to overcome.

Discussion: Non-contrast MRI future trends are likely represented by PCa screening and the application of artificial intelligence (AI) tools. PCa screening is still a controversial topic; bpMRI has become one of the most promising diagnostic applications, as it is a more sensitive test for PCa early detection, compared to serum PSA level test. Also, AI applications and radiomic have been the object of several studies investigating PCa detection using bpMRI, showing encouraging results.

Conclusion: Today, the accessibility to MRI for early detection of PCa is a priority. Results from prospective, multicenter, multireader, and paired validation studies are needed to provide evidence supporting its role in the clinical practice.

Keywords: PI-RADS; contrast-enhanced MRI; non-contrast-enhanced MRI; prostate cancer; prostate cancer screening.

PubMed Disclaimer

References

REFERENCES

    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. https://doi.org/10.14740/wjon1191.
    1. Pollock PA, Ludgate A, Wassersug RJ. In 2124, half of all men can count on developing prostate cancer. Curr Oncol. 2014;22(1):10. https://doi.org/10.3747/co.22.2102.
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015;136(5):E359-E386. https://doi.org/10.1002/ijc.29210.
    1. Wegelin O, Exterkate L, van der Leest M, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75(4):582-590. https://doi.org/10.1016/j.eururo.2018.11.040.
    1. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132-142. https://doi.org/10.1056/NEJMoa1615869.

MeSH terms

LinkOut - more resources